Boston Scientific Operating Margin 2010-2025 | BSX
Current and historical operating margin for Boston Scientific (BSX) over the last 10 years. The current operating profit margin for Boston Scientific as of June 30, 2025 is 22.86%.
| Boston Scientific Operating Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM Operating Income | Operating Margin |
| 2025-06-30 | $18.50B | $3.15B | 17.05% |
| 2025-03-31 | $17.55B | $2.85B | 16.26% |
| 2024-12-31 | $16.75B | $2.61B | 15.56% |
| 2024-09-30 | $15.91B | $2.51B | 15.79% |
| 2024-06-30 | $15.23B | $2.47B | 16.23% |
| 2024-03-31 | $14.71B | $2.47B | 16.76% |
| 2023-12-31 | $14.24B | $2.34B | 16.45% |
| 2023-09-30 | $13.76B | $2.16B | 15.69% |
| 2023-06-30 | $13.40B | $1.82B | 13.61% |
| 2023-03-31 | $13.05B | $1.73B | 13.28% |
| 2022-12-31 | $12.68B | $1.65B | 12.99% |
| 2022-09-30 | $12.57B | $1.43B | 11.35% |
| 2022-06-30 | $12.33B | $1.46B | 11.80% |
| 2022-03-31 | $12.16B | $1.30B | 10.65% |
| 2021-12-31 | $11.89B | $1.20B | 10.08% |
| 2021-09-30 | $11.47B | $1.07B | 9.32% |
| 2021-06-30 | $11.20B | $0.48B | 4.25% |
| 2021-03-31 | $10.12B | $0.14B | 1.42% |
| 2020-12-31 | $9.91B | $-0.08B | -0.80% |
| 2020-09-30 | $10.11B | $0.08B | 0.78% |
| 2020-06-30 | $10.16B | $0.67B | 6.58% |
| 2020-03-31 | $10.79B | $1.12B | 10.40% |
| 2019-12-31 | $10.74B | $1.52B | 14.13% |
| 2019-09-30 | $10.39B | $1.63B | 15.65% |
| 2019-06-30 | $10.08B | $1.63B | 16.19% |
| 2019-03-31 | $9.94B | $1.64B | 16.49% |
| 2018-12-31 | $9.82B | $1.51B | 15.33% |
| 2018-09-30 | $9.67B | $1.51B | 15.58% |
| 2018-06-30 | $9.50B | $1.50B | 15.74% |
| 2018-03-31 | $9.27B | $1.33B | 14.34% |
| 2017-12-31 | $9.05B | $1.29B | 14.20% |
| 2017-09-30 | $8.83B | $1.11B | 12.53% |
| 2017-06-30 | $8.71B | $1.08B | 12.36% |
| 2017-03-31 | $8.58B | $0.52B | 6.04% |
| 2016-12-31 | $8.39B | $0.45B | 5.33% |
| 2016-09-30 | $8.17B | $0.08B | 0.98% |
| 2016-06-30 | $7.96B | $-0.57B | -7.13% |
| 2016-03-31 | $7.67B | $-0.01B | -0.18% |
| 2015-12-31 | $7.48B | $-0.28B | -3.78% |
| 2015-09-30 | $7.39B | $-0.55B | -7.43% |
| 2015-06-30 | $7.34B | $-0.19B | -2.53% |
| 2015-03-31 | $7.37B | $-0.47B | -6.43% |
| 2014-12-31 | $7.38B | $-0.30B | -4.08% |
| 2014-09-30 | $7.33B | $0.32B | 4.35% |
| 2014-06-30 | $7.22B | $0.36B | 4.96% |
| 2014-03-31 | $7.16B | $0.65B | 9.04% |
| 2013-12-31 | $7.14B | $0.12B | 1.68% |
| 2013-09-30 | $7.13B | $0.11B | 1.54% |
| 2013-06-30 | $7.13B | $-0.59B | -8.24% |
| 2013-03-31 | $7.14B | $-4.39B | -61.51% |
| 2012-12-31 | $7.25B | $-3.87B | -53.36% |
| 2012-09-30 | $7.28B | $-3.81B | -52.41% |
| 2012-06-30 | $7.42B | $-3.05B | -41.07% |
| 2012-03-31 | $7.56B | $0.78B | 10.29% |
| 2011-12-31 | $7.62B | $0.90B | 11.86% |
| 2011-09-30 | $7.78B | $1.08B | 13.90% |
| 2011-06-30 | $7.82B | $1.16B | 14.81% |
| 2011-03-31 | $7.77B | $1.15B | 14.82% |
| 2010-12-31 | $7.81B | $-0.66B | -8.40% |
| 2010-09-30 | $7.88B | $-2.24B | -28.35% |
| 2010-06-30 | $7.99B | $-2.44B | -30.47% |
| 2010-03-31 | $8.14B | $-2.39B | -29.38% |
| 2009-12-31 | $8.19B | $-0.89B | -10.92% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $152.872B | $16.747B |
| Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments - Cardiovascular, Rhythm and Neuro and MedSurg. While Cardiovascular includes Interventional Cardiology and Peripheral Interventions, Rhythm and Neuro comprises Cardiac Rhythm Management, Electrophysiology and Neuromodulation. The MedSurg group comprises 2 sub segments, viz. Endoscopy, Urology and Pelvic Health. Boston Scientific markets a broad portfolio of internally-developed and self-manufactured drug eluting stents including the Promus PREMIER, Promus Element and Promus Element Plus everolimus-eluting stents. Within the CRM segment, the company deals with implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $229.305B | 26.89 |
| Stryker (SYK) | United States | $146.007B | 29.72 |
| EssilorLuxottica (ESLOY) | France | $145.127B | 0.00 |
| Medtronic (MDT) | Ireland | $119.233B | 16.91 |
| Lonza Group Ag (LZAGY) | Switzerland | $48.282B | 0.00 |
| Haleon (HLN) | United Kingdom | $43.313B | 24.74 |
| ResMed (RMD) | United States | $41.712B | 29.83 |
| Agilent Technologies (A) | United States | $33.861B | 22.07 |
| GE HealthCare Technologies (GEHC) | United States | $33.512B | 15.75 |
| Terumo (TRUMY) | Japan | $27.642B | 32.75 |
| Koninklijke Philips (PHG) | Netherlands | $26.451B | 17.50 |
| Insulet (PODD) | United States | $22.615B | 75.77 |
| Zimmer Biomet Holdings (ZBH) | United States | $20.354B | 12.96 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $15.855B | 0.00 |
| Baxter (BAX) | United States | $12.419B | 9.60 |
| Sunny Optical Technology (SNPTF) | China | $10.800B | 0.00 |
| Demant (WILYY) | Denmark | $8.121B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $7.731B | 28.40 |
| Lantheus Holdings (LNTH) | United States | $3.684B | 9.96 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Envista Holdings (NVST) | United States | $3.430B | 24.00 |
| Prestige Consumer Healthcare (PBH) | United States | $3.198B | 14.19 |
| Perrigo (PRGO) | Ireland | $3.123B | 7.80 |
| ICU Medical (ICUI) | United States | $2.986B | 20.33 |
| Haemonetics (HAE) | United States | $2.589B | 11.56 |
| LeMaitre Vascular (LMAT) | United States | $2.171B | 46.56 |
| Curaleaf Holdings (CURLF) | Canada | $1.782B | 0.00 |
| AtriCure (ATRC) | United States | $1.762B | 0.00 |
| QuidelOrtho (QDEL) | United States | $1.761B | 11.08 |
| Green Thumb Industries (GTBIF) | United States | $1.601B | 68.73 |
| AdaptHealth (AHCO) | United States | $1.283B | 18.24 |
| Phibro Animal Health (PAHC) | United States | $1.243B | 15.89 |
| Acuren (TIC) | United States | $1.190B | 0.00 |
| Neogen (NEOG) | United States | $1.179B | 18.72 |
| BioLife Solutions (BLFS) | United States | $1.166B | 2434.00 |
| Tilray Brands (TLRY) | Canada | $1.134B | 0.00 |
| Valneva SE (VALN) | France | $0.981B | 0.00 |
| InMode (INMD) | Israel | $0.907B | 8.39 |
| Kestra Medical Technologies (KMTS) | United States | $0.824B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.665B | 0.00 |
| Surmodics (SRDX) | United States | $0.536B | 0.00 |
| ZimVie (ZIMV) | United States | $0.532B | 20.49 |
| SNDL (SNDL) | Canada | $0.531B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.482B | 0.00 |
| CeriBell (CBLL) | United States | $0.451B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.451B | 15.53 |
| Owens & Minor (OMI) | United States | $0.439B | 3.89 |
| Verano Holdings (VRNOF) | United States | $0.438B | 0.00 |
| Evolus (EOLS) | United States | $0.435B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.364B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.331B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.330B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.312B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.287B | 0.00 |
| Omeros (OMER) | United States | $0.272B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.267B | 20.26 |
| Sanara MedTech (SMTI) | United States | $0.264B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.254B | 0.00 |
| Brainsway (BWAY) | Israel | $0.245B | 49.92 |
| Cerus (CERS) | United States | $0.238B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.234B | 0.00 |
| High Tide (HITI) | Canada | $0.216B | 0.00 |
| Quanterix (QTRX) | United States | $0.212B | 0.00 |
| Exagen (XGN) | United States | $0.209B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.202B | 0.00 |
| Organigram Global (OGI) | Canada | $0.192B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.178B | 14.83 |
| TriSalus Life Sciences (TLSI) | United States | $0.172B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.156B | 0.00 |
| Biote (BTMD) | United States | $0.144B | 4.79 |
| Jushi Holdings (JUSHF) | United States | $0.116B | 0.00 |
| MacroGenics (MGNX) | United States | $0.100B | 0.00 |
| Jin Medical (ZJYL) | China | $0.096B | 0.00 |
| Fonar (FONR) | United States | $0.094B | 12.08 |
| Quipt Home Medical (QIPT) | United States | $0.089B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.085B | 0.00 |
| Apyx Medical (APYX) | United States | $0.082B | 0.00 |
| Safety Shot (SHOT) | United States | $0.078B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.073B | 0.00 |
| Agape ATP (ATPC) | $0.063B | 0.00 | |
| ImmuCell (ICCC) | United States | $0.055B | 32.12 |
| Veru (VERU) | United States | $0.053B | 0.00 |
| Zynex (ZYXI) | United States | $0.046B | 0.00 |
| Nephros (NEPH) | United States | $0.045B | 35.42 |
| Modular Medical (MODD) | United States | $0.039B | 0.00 |
| United-Guardian (UG) | United States | $0.036B | 14.05 |
| Rockwell Medical (RMTI) | United States | $0.035B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.029B | 0.00 |
| Senestech (SNES) | United States | $0.024B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.018B | 0.00 |
| INLIF (INLF) | $0.017B | 0.00 | |
| Flora Growth (FLGC) | United States | $0.014B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.014B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.012B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.009B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.008B | 0.00 |
| Sharps Technology (STSS) | United States | $0.005B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| InterCure (INCR) | Israel | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |